The withdrawal of Oxbryta (voxelotor) from global markets, announced by Pfizer after a recent data review revealed a rise in deaths and complications, has left sickle cell disease (SCD) patients in a precarious situation. The sudden nature of the announcement caught the patient and physician community off guard, as there was no prewarning. For an
Navigating patient transitions following the withdrawal of Oxbryta originally appeared in KevinMD.com.
